Association between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer’s disease
By
Yali Chen
Xia Zhou
Kaigui Wang
He Feng
Bo Tian
Yating Tang
Xiaoqun Zhu
Zhongwu Sun
May 11, 2026
Clinical Scorecard: Linking Circulating One-Carbon Metabolism Biomarkers to Glymphatic System Activity in Alzheimer's Disease-Related Cognitive Decline
At a Glance
Category Detail
Condition Alzheimer's Disease (AD) Key Mechanisms One-carbon metabolism (OCM) and glymphatic system function Target Population Adults with normal cognition, mild cognitive impairment due to AD, and dementia due to AD Care Setting Clinical research setting
Key Highlights
Lower serum folate levels and reduced DTI-ALPS index linked to poorer cognitive performance in AD. Significant differences in serum folate and DTI-ALPS index between normal cognition and AD groups. High folate and DTI-ALPS index associated with better memory and processing speed outcomes. Guideline-Based Recommendations
Diagnosis
Evaluate serum folate, vitamin B12, and homocysteine levels in AD patients. Use DTI-ALPS index for assessing glymphatic function. Management
Consider folate and B-vitamin supplementation to lower homocysteine levels. Monitor cognitive performance in relation to OCM biomarkers. Monitoring & Follow-up
Regular assessment of serum folate and DTI-ALPS index in AD patients. Risks
Inadequate dietary intake of folate and B-vitamins may exacerbate AD progression. Patient & Prescribing Data
Adults diagnosed with Alzheimer's disease at various stages.
Folate supplementation may provide antioxidant effects and improve cognitive outcomes.
Clinical Best Practices
Integrate nutritional assessments into routine evaluations for AD patients. Encourage dietary intake of folate and B-vitamins as part of AD management. Related Resources & Content
